Strontium-89 Therapy
Strontium-89 Therapy is a form of radionuclide therapy that utilizes the beta-emitting isotope strontium-89 to selectively target and ablate bone metastases by mimicking calcium uptake in areas of increased osteoblastic activity.
170
Publications
7.6K
Citations
702
Authors
265
Institutions
Publications per year
2017–2026
7
Variants
89Sr Therapy
Parents
170
Arthur T. Porter, Alexander McEwan, John Powe et al. · International Journal of Radiation Oncology*Biology*Physics · 1993 · 532 citations
Valerie Lewington, Alexander McEwan, Duncan Ackery et al. · European Journal of Cancer and Clinical Oncology · 1991 · 279 citations
Strontium-89 chloride for pain palliation in prostatic skeletal malignancy
A. H. Laing, D. M. Ackery, R. J. Bayly et al. · British Journal of Radiology · 1991 · 218 citations
Medicine, Oncology, Pharmacotherapy +13
1–5 of 170
702
7
h-index
6
h-index
6
h-index
6
h-index
6
h-index
1–5 of 702
265

Southampton General Hospital
Southampton, United Kingdom
8 h-index
22 publications
2.3K citations
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
5 h-index
6 publications
860 citations
The University of Texas MD Anderson Cancer Center
Houston, United States
5 h-index
36 publications
1.3K citations
Birmingham City Hospital
Birmingham, United Kingdom
4 h-index
4 publications
186 citations
The Christie Hospital
Manchester, United Kingdom
4 h-index
4 publications
186 citations

University of Birmingham
Birmingham, United Kingdom
4 h-index
23 publications
1.1K citations

Royal Derby Hospital
Derby, United Kingdom
4 h-index
4 publications
186 citations
Wayne State University
Detroit, United States
4 h-index
5 publications
678 citations
1–8 of 265
Repository · 31 publications · 1.1K citations
19
h-index
13 publications · 908 citations
12
h-index
6 publications · 803 citations
6
h-index
6 publications · 202 citations
6
h-index
BJR · 6 publications · 339 citations
6
h-index
1–5